Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase II study of PN-101 for patients with rare diseases polymyositis/dermatomyositis

Next Previous
X
Search
Trial Profile

A phase II study of PN-101 for patients with rare diseases polymyositis/dermatomyositis

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 04 Mar 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PN-101 (Primary)
  • Indications Dermatomyositis; Polymyositis
  • Focus Therapeutic Use

    • Most Recent Events

    • 04 Mar 2025 New trial record
    • 07 Feb 2025 According to PAEAN Biotechnology media release, PN-101 is currently undergoing IND review with the Ministry of Food and Drug Safety for approval of Phase 2 clinical trials, and after approval, clinical trials to confirm the safety and efficacy of PN-101 are expected to be conducted in 2025.
    • 07 Feb 2025 According to PAEAN Biotechnology media release, in this multicenter study, Professor Eunyoung Lee of the Department of Rheumatology at Seoul National University Hospital, Professor Hyunsook Kim of the Department of Rheumatology at Soon Chun Hyang University Hospital in Seoul, and Professor Yeona Lee of the Department of Rheumatology at Kyung Hee University Hospital are participated.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top